An evidence-based medicine strategy for achieving remission in bipolar disorder

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 3, 2008, Pages 31-37

  Beyer, John L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EVIDENCE BASED MEDICINE; HAMILTON SCALE; HUMAN; MANIA RATING SCALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; REMISSION; REVIEW; YOUNG MANIA RATING SCALE; ADDICTION; METHODOLOGY; PATIENT COMPLIANCE;

BIPOLAR DISORDER; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT COMPLIANCE; REMISSION INDUCTION; SUBSTANCE-RELATED DISORDERS;

EID: 46649088603     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-516
2. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
3. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
4. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
5. Joffe RT, MacQueen GM, Marriott M, et al. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord 2004;6:62-66
6. Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002;63:807-811
7. Zhang H, Wisniewski SR, Bauer MS, et al. Comparisons of perceived quality of life across clinical states in bipolar disorder: data from the first 2000 Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) participants. Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Investigators. Compr Psychiatry 2006;47:161-168
8. Fagiolini A, Kupfer DJ, Masalehdan A, et al. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005;7:281-285
9. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-1111
10. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163:217-224
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000
12. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 2002;159(suppl 4):1-50
13. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435
14. Bech P, Bolwig TG, Kramp P, et al. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 1979;59:420-430
15. Guy W. ECDEU Assessment Manual for Psychopharmacology (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
16. Hilsenroth MJ, Ackerman SJ, Blagys MD, et al. Reliability and validity of DSM-IV Axis V. Am J Psychiatry 2000;157:1858-1863
17. Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale: reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-659
18. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatr Serv 2005;56:735-742
19. MacQueen GM, Marriott M, Begin H, et al. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord 2003;5:349-355
20. Ketter TA, Wang PW, Nowakowska C, et al. Treatment of acute mania in bipolar disorder. In: Ketter TA, ed. Advances in the Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Press; 2005:11-55
21. Gopal S, Steffens DC, Kramer ML, et al. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005;66:1016-1020
22. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005;21:923-934
23. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-242
24. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226
25. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-585
26. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111-121
27. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-1017
28. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-1271
29. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606
30. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-223
31. Potkin SG, Keck P, Giller E, et al. Ziprasidone in bipolar mania: efficacy across patient subgroups [poster]. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; New York, NY
32. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-1065
33. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408
34. Calabrese JR, Kasper S, Johnson G, et al. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry 2004 Apr;65(4):569-579
35. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88
36. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-912
37. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002;4:207-213
38. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-512
39. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006;96:95-99
40. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-131
41. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004;65:1715-1719
42. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088
43. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360
44. Brown EB, McElroy SL, Keck PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006;67:1025-1033
45. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-1547
46. Chengappa KN, Hennen J, Baldessarini RJ, et al. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord 2005;7:68-76
47. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:2099-2107
48. Morgan VA, Mitchell PB, Jablensky AV. The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. Bipolar Disord 2005;7:326-337
49. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003;53:1028-1042
50. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-172
51. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995;152:379-384
52. Tsai SM, Chen C, Kuo C, et al. 15-year outcome of treated bipolar disorder. J Affect Disord 2001;63:215-220
53. Nolen WA, Luckenbaugh DA, Altshuler LL, et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004;161:1447-1454
54. Coryell W, Turvey C, Endicott J, et al. Bipolar I affective disorder: predictors of outcome after 15 years. J Affect Disord 1998;50:109-116